Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference
- PMID: 16150960
- DOI: 10.1093/schbul/sbi047
Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference
Abstract
At the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) New Approaches Conference, a discussion group focused on directions for future research that are critical to enhancing our understanding of the distinctions among key cognitive domains that have relevance for the development of cognition-enhancing interventions. One set of recommendations emphasizes the need for examining and optimizing the psychometric properties of relevant measurement paradigms from cognitive psychology and cognitive neuroscience. This step is critical to translating many notable advances in these basic fields into measures that would be appropriate for clinical trials. A second set of recommendations focuses on key directions for the development and application of animal models of cognitive processes that would greatly aid the discovery and preclinical testing of potential cognition-enhancing agents. As part of this process, the group noted several existing animal paradigms that have particular promise as measures in the key cognitive domains in schizophrenia identified by the MATRICS Neurocognition Committee.
Similar articles
-
Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference.Schizophr Bull. 2005 Oct;31(4):882-7. doi: 10.1093/schbul/sbi049. Epub 2005 Aug 31. Schizophr Bull. 2005. PMID: 16135561
-
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.Schizophr Bull. 2005 Oct;31(4):888-94. doi: 10.1093/schbul/sbi041. Epub 2005 Aug 3. Schizophr Bull. 2005. PMID: 16079387
-
Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.Schizophr Bull. 2005 Oct;31(4):810-5. doi: 10.1093/schbul/sbi046. Epub 2005 Aug 17. Schizophr Bull. 2005. PMID: 16107584 Review.
-
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.Biol Psychiatry. 2004 Sep 1;56(5):301-7. doi: 10.1016/j.biopsych.2004.06.023. Biol Psychiatry. 2004. PMID: 15336511 Review.
-
Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Clin Ther. 2008. PMID: 18840365 Review.
Cited by
-
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.J Psychopharmacol. 2015 Feb;29(2):178-96. doi: 10.1177/0269881114555252. Epub 2014 Dec 16. J Psychopharmacol. 2015. PMID: 25516372 Free PMC article. Review.
-
The reliability and validity of the MATRICS functional assessment battery.Schizophr Bull. 2014 Sep;40(5):1047-52. doi: 10.1093/schbul/sbt148. Epub 2013 Nov 9. Schizophr Bull. 2014. PMID: 24214931 Free PMC article.
-
Sustained attention in mice: expanding the translational utility of the SAT by incorporating the Michigan Controlled Access Response Port (MICARP).Behav Brain Res. 2011 Dec 1;225(2):574-83. doi: 10.1016/j.bbr.2011.08.025. Epub 2011 Aug 22. Behav Brain Res. 2011. PMID: 21888929 Free PMC article.
-
Dysconnection and cognition in schizophrenia: A spectral dynamic causal modeling study.Hum Brain Mapp. 2023 May;44(7):2873-2896. doi: 10.1002/hbm.26251. Epub 2023 Feb 28. Hum Brain Mapp. 2023. PMID: 36852654 Free PMC article.
-
Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.Schizophr Bull. 2008 Jul;34(4):613-8. doi: 10.1093/schbul/sbn037. Epub 2008 May 21. Schizophr Bull. 2008. PMID: 18499705 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials